Recruiting NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma NCT07211737 Conditions Neoplasms, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, +16 more Locations Texas Children's Hospital — Houston, Texas, United States View Trial Details
Recruiting Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma NCT07144254 Conditions Neoplasms, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, +8 more Locations Arthur M. Blank Children's Healthcare of Atlanta — Atlanta, Georgia, United States View Trial Details
Recruiting Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma NCT05400603 Conditions Neoplasms, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, +16 more Locations Children's Healthcare of Atlanta — Atlanta, Georgia, United States View Trial Details
Completed Cabozantinib With Topotecan-Cyclophosphamide NCT04661852 Conditions Neoplasms, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, +9 more Locations Boston Children's Hospital — Boston, Massachusetts, United States Dana-Farber Cancer Institute — Boston, Massachusetts, United States View Trial Details
Completed Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma NCT01804374 Conditions Metastatic Osteosarcoma, Neoplasms, Neoplasms by Histologic Type, +6 more Locations Fondazione del Piemonte per l'Oncologia IRCC Candiolo — Candiolo, Torino, Italy View Trial Details
Active, Not Recruiting C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) NCT03635632 Conditions Breast Diseases, Breast Neoplasms, Eye Diseases, +36 more Locations Houston Methodist Hospital — Houston, Texas, United States Texas Children's Hospital — Houston, Texas, United States View Trial Details
